Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis. PLOS One. 2014; 9(8): e104300. DOI: https://doi.org/10.1371/journal.pone.0104300 

World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014. 

Mungal-Singh V. Lifestyle changes for hypertension: SA Hypertension Society Supplement. South African Family Practice. 2012; 54(2): S12–S16. DOI: https://doi.org/10.1080/20786204.2012.10874203 

Kamran A, Ahari SS, Biria M, Malpour A, Heydari H. Determinants of patient’s adherence to hypertension medications: Application of health belief model among rural patients. Annals of Medical and Health Sciences Research. 2014; 4(6): 922–927. DOI: https://doi.org/10.4103/2141-9248.144914 

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51(6): 1403–1419. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.108.189141 

Ambaw AD, Alemie GA, Mengesha ZB. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012; 12(1): 1–6. DOI: https://doi.org/10.1186/1471-2458-12-282 

Kably B, Billaud EM, Boutouyrie P, Azizi M. Is there any hope for monitoring adherence in an efficient and feasible way for resistant hypertension diagnosis and follow-up? Current Hypertension Reports. 2020; 22(11): 1–7. DOI: https://doi.org/10.1007/s11906-020-01105-6 

van der Linden EL, Agyemang C, van den Born BJH. Hypertension control in sub-Saharan Africa: Clinical inertia is another elephant in the room. Journal of Clinical Hypertension (Greenwich). 2020; 22(6): 959–961. DOI: https://doi.org/10.1111/jch.13874 

Muhamedhussein MS, Nagri ZI, Manji KP. Prevalence, risk factors, awareness, and treatment and control of hypertension in Mafia Island, Tanzania. International Journal of Hypertension. 2016; 2016: 1281384. DOI: https://doi.org/10.1155/2016/1281384 

Nielsen JØ, Shrestha A, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: A systematic review and meta-analysis of 92443 subjects. Journal of Human Hypertension. 2017; 31(1): 14–21. DOI: https://doi.org/10.1038/jhh.2016.31 

Burnier M, Wuerzner G. Qualitative assessments of adherence. In: Burnier M (Ed.), Drug adherence in hypertension and cardiovascular protection. 2018; 11–19. Cham: Springer. DOI: https://doi.org/10.1007/978-3-319-76593-8_2 

Gwadry-Sridhar FH, Manias E, Lal L, Salas M, Hughes DA, Ratzki-Leewing A, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: A systematic review by the ISPOR medication adherence and persistence special interest group. Value in Health. 2013; 16(5): 863–871. DOI: https://doi.org/10.1016/j.jval.2013.03.1631 

Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, et al. Medication adherence and blood pressure control: A scientific statement from the American Heart Association. Hypertension. 2022; 79(1): e1–e14. DOI: https://doi.org/10.1161/HYP.0000000000000203 

Chauke GD, Nakwafila O, Chibi B, Sartorius B, Mashamba-Thompson T. Factors influencing poor medication adherence amongst patients with chronic disease in low- and-middle-income countries: A systematic scoping review. Heliyon. 2022; 8(6): e09716. DOI: https://doi.org/10.1016/j.heliyon.2022.e09716 

Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Therapeutics and Clinical Risk Management. 2005; 1(3): 189–199. 

Iuga AO, McGuire MJ. Adherence and health care costs. Risk Management and Healthcare Policy. 2014; 7: 35. DOI: https://doi.org/10.2147/RMHP.S19801 

Jankowska-Polańska B, Uchmanowicz B, Szymańska-Chabowska A. Assessment of adherence to medication for cardiovascular diseases: measurement tools. Cardiovascular Journal of Africa. 2019; 30(2): 113–119. DOI: https://doi.org/10.5830/CVJA-2018-050 

Bernard L, Peytavin G. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy. Lancet. 1998; 352(9142): 1757–1758. DOI: https://doi.org/10.1016/S0140-6736(05)79831-7 

Bernard L, Vuagnat A, Peytavin G, Hallouin M-C, Bouhour D, Nguyen TH, et al. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Annals of Internal Medicine. 2002; 137(8): 656–659. DOI: https://doi.org/10.7326/0003-4819-137-8-200210150-00009 

Gandhi M, Ameli N, Bacchetti P, Gange SJ, Anastos K, Levine A, et al. Protease inhibitor levels in hair samples strongly predict virologic responses to HIV treatment. AIDS (London, England). 2009; 23(4): 471–478. DOI: https://doi.org/10.1097/QAD.0b013e328325a4a9 

Kintz P. Evidence of 2 populations of mephedrone abusers by hair testing. Application to 4 forensic expertises. Current Neuropharmacology. 2017; 15(5): 658–662. DOI: https://doi.org/10.2174/1570159X14666161026152107 

Robbins CR. Chemical composition of different hair types. In: Chemical and physical behavior of human hair. 2012; 105–176. Berlin; Springer-Verlag. DOI: https://doi.org/10.1007/978-3-642-25611-0_2 

Gandhi M, Devi S, Bacchetti P, Chandy S, Heylen E, Phung N, et al. Measuring adherence to antiretroviral therapy via hair concentrations in India. Journal of Acquired Immune Deficiency Syndromes (1999). 2019; 81(2): 202–206. DOI: https://doi.org/10.1097/QAI.0000000000001993 

Taus F, Gottardo R, Ballotari M, Utzeri C, Tagliaro F. Hair analysis for beta-blockers and calcium-channel blockers by using liquid chromatography-tandem mass spectrometry as a tool for monitoring adherence to antihypertensive therapy. Drug Testing Analysis. 2022; 14(10): 1773–1778. DOI: https://doi.org/10.1002/dta.3346 

Lam WY, Fresco P. Medication adherence measures: An overview. BioMed Research International. 2015; 217047. DOI: https://doi.org/10.1155/2015/217047 

Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: Still no better than a coin toss. BMC Health Services Research. 2012; 12(1): 1–11. DOI: https://doi.org/10.1186/1472-6963-12-270 

Durand H, Casey M, Glynn LG, Hayes P, Murphy AW, Molloy GJ. A qualitative comparison of high and low adherers with apparent treatment-resistant hypertension. Psychology, Health & Medicine. 2020; 25(1): 64–77. DOI: https://doi.org/10.1080/13548506.2019.1619788 

Atinga RA, Yarney L, Gavu NM. Factors influencing long-term medication non-adherence among diabetes and hypertensive patients in Ghana: A qualitative investigation. PLOS One. 2018; 13(3): e0193995. DOI: https://doi.org/10.1371/journal.pone.0193995 

Cremers AL, Alege A, Nelissen HE, Okwor TJ, Osibogun A, Gerrets R, et al. Patients’ and healthcare providers’ perceptions and practices regarding hypertension, pharmacy-based care, and mHealth in Lagos, Nigeria: A mixed methods study. Journal of Hypertension. 2019; 37(2): 389–397. DOI: https://doi.org/10.1097/HJH.0000000000001877 

Najjuma JN, Brennaman L, Nabirye RC, Ssedyabane F, Maling S, Bajunirwe F, et al. Adherence to antihypertensive medication: An interview analysis of southwest Ugandan patients’ perspectives. Annals of Global Health. 2020; 86(1): 58. DOI: https://doi.org/10.5334/aogh.2904 

Adebolu FA, Naidoo M. Blood pressure control amongst patients living with hypertension presenting to an urban district hospital outpatient clinic in Kwazulu-Natal. African Journal of Primary Health Care & Family Medicine. 2014; 6(1): E1–6. DOI: https://doi.org/10.4102/phcfm.v6i1.572 

Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Annals of Pharmacotherapy. 2004; 38(2): 303–312. DOI: https://doi.org/10.1345/aph.1D252 

Zeller A, Taegtmeyer A, Martina B, Battegay E, Tschudi P. Physicians’ ability to predict patients’ adherence to antihypertensive medication in primary care. Hypertension Research. 2008; 31(9): 1765–1771. DOI: https://doi.org/10.1291/hypres.31.1765 

Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013; 62(2): 218–225. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.113.00687 

Fodor GJ, Kotrec M, Bacskai K, Dorner T, Lietava J, Sonkodi S, et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. Journal of Hypertension. 2005; 23(6): 1261–1266. DOI: https://doi.org/10.1097/01.hjh.0000170390.07321.ca 

Pérez-Escamilla B, Franco-Trigo L, Moullin JC, Martínez-Martínez F, García-Corpas JP. Identification of validated questionnaires to measure adherence to pharmacological antihypertensive treatments. Patient Preference and Adherence. 2015; 9: 569. DOI: https://doi.org/10.2147/PPA.S76139 

Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986; 67–74. DOI: https://doi.org/10.1097/00005650-198601000-00007 

Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Progress in Cardiovascular Nursing. 2000; 15(3): 90–96. DOI: https://doi.org/10.1111/j.1751-7117.2000.tb00211.x 

Schroeder K, Fahey T, Hay AD, Montgomery A, Peters TJ. Adherence to antihypertensive medication assessed by self-report was associated with electronic monitoring compliance. Journal of Clinical Epidemiology. 2006; 59(6): 650–651. DOI: https://doi.org/10.1016/j.jclinepi.2005.10.013 

Willey C, Redding C, Stafford J, Garfield F, Geletko S, Flanigan T, et al. Stages of change for adherence with medication regimens for chronic disease: Development and validation of a measure. Clinical Therapeutics. 2000; 22(7): 858–871. DOI: https://doi.org/10.1016/S0149-2918(00)80058-2 

Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: A tool for screening patient adherence and barriers to adherence. Patient Education and Counseling. 1999; 37(2): 113–124. DOI: https://doi.org/10.1016/S0738-3991(98)00107-4 

Culig J, Leppee M. From Morisky to Hill-Bone; self-reports scales for measuring adherence to medication. Collegium Antropologicum. 2014; 38(1): 55–62. 

Hamilton GA. Measuring adherence in a hypertension clinical trial. European Journal of Cardiovascular Nursing. 2003; 2(3): 219–228. DOI: https://doi.org/10.1016/S1474-5151(03)00058-6 

Nashilongo M, Singu B, Kalemeera F, Mubita M, Naikaku E, Baker A, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: Findings and implications. Cardiovascular Drugs and Therapy. 2017; 31(5): 565–578. DOI: https://doi.org/10.1007/s10557-017-6756-8 

Sarkodie E, Afriyie DK, Hutton-Nyameaye A, Amponsah SK. Adherence to drug therapy among hypertensive patients attending two district hospitals in Ghana. African Health Sciences. 2020; 20(3): 1355–1367. DOI: https://doi.org/10.4314/ahs.v20i3.42 

Ayodapo A, Elegbede O, Omosanya O, Monsudi K. Patient education and medication adherence among hypertensives in a tertiary hospital, South Western Nigeria. Ethiopian Journal of Health Sciences. 2020; 30(2): 243–250. DOI: https://doi.org/10.4314/ejhs.v30i2.12 

Okunrinboye HI, Otakpor AN, Ilesanmi OS. Depression and medication-adherence in patients with hypertension attending a tertiary health facility in South-West Nigeria. Pan African Medical Journal. 2019; 33: 27. DOI: https://doi.org/10.11604/pamj.2019.33.27.12941 

Mekonnen HS, Gebrie MH, Eyasu KH, Gelagay AA. Drug adherence for antihypertensive medications and its determinants among adult hypertensive patients attending in chronic clinics of referral hospitals in Northwest Ethiopia. BMC Pharmacology and Toxicology. 2017; 18(1): 1–10. DOI: https://doi.org/10.1186/s40360-017-0134-9 

Mugwano I, Kaddumukasa M, Mugenyi L, Kayima J, Ddumba E, Sajatovic M, et al. Poor drug adherence and lack of awareness of hypertension among hypertensive stroke patients in Kampala, Uganda: A cross sectional study. BMC Research Notes. 2016; 9(1): 1–8. DOI: https://doi.org/10.1186/s13104-015-1830-4 

de Terline DM, Kramoh KE, Diop IB, Nhavoto C, Balde DM, Ferreira B, et al. Poor adherence to medication and salt restriction as a barrier to reaching blood pressure control in patients with hypertension: Cross-sectional study from 12 sub-Saharan countries. Archives of Cardiovascular Diseases. 2020; 113(6–7): 433–442. DOI: https://doi.org/10.1016/j.acvd.2019.11.009 

Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, et al. Validation of a French version of the 8-item Morisky Medication Adherence Scale in hypertensive adults. Journal of Clinical Hypertension. 2012; 14(7): 429–434. DOI: https://doi.org/10.1111/j.1751-7176.2012.00634.x 

Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine. 2017; 96(4): e5641. DOI: https://doi.org/10.1097/MD.0000000000005641 

Adeoye AM, Adebiyi AO, Adebayo OM, Owolabi MO. Medication adherence and 24-h blood pressure in apparently uncontrolled hypertensive Nigerian patients. Nigerian Postgraduate Medical Journal. 2019; 26(1): 18. DOI: https://doi.org/10.4103/npmj.npmj_147_18 

Okunrinboye HI, Otakpor AN, Ilesanmi OS. Depression and medication-adherence in patients with hypertension attending a tertiary health facility in south-west Nigeria. Pan African Medical Journal. 2019; 33: 27. DOI: https://doi.org/10.11604/pamj.2019.33.27.12941 

Oluwole EO, Osibogun O, Adegoke O, Adejimi AA, Adewole AM, Osibogun A. Medication adherence and patient satisfaction among hypertensive patients attending outpatient clinic in Lagos University Teaching Hospital, Nigeria. Nigerian Postgraduate Medical Journal. 2019; 26(2): 129. DOI: https://doi.org/10.4103/npmj.npmj_48_19 

Adisa R, Ilesanmi OA, Fakeye TO. Treatment adherence and blood pressure outcome among hypertensive out-patients in two tertiary hospitals in Sokoto, Northwestern Nigeria. BMC Cardiovascular Disorders. 2018; 18(1): 1–10. DOI: https://doi.org/10.1186/s12872-018-0934-x 

Olowe OA, Ross AJ. Knowledge, adherence and control among patients with hypertension attending a peri-urban primary health care clinic, KwaZulu-Natal. African Journal of Primary Health Care & Family Medicine. 2017; 9(1): e1–e7. DOI: https://doi.org/10.4102/phcfm.v9i1.1456 

Lambert EV, Steyn K, Stender S, Everage N, Fourie JM. Cross-cultural validation of the Hill-Bone Compliance to High Blood Pressure Therapy Scale in a South African, primary healthcare setting. Ethnicity and Disease. 2006; 16(1): 286. 

Koschack J, Marx G, Schnakenberg J, Kochen MM, Himmel W. Comparison of two self-rating instruments for medication adherence assessment in hypertension revealed insufficient psychometric properties. Journal of Clinical Epidemiology. 2010; 63(3): 299–306. DOI: https://doi.org/10.1016/j.jclinepi.2009.06.011 

Karademir M, Koseoglu IH, Vatansever K, Van Den Akker M. Validity and reliability of the Turkish version of the Hill-Bone Compliance to High Blood Pressure Therapy Scale for use in primary health care settings. European Journal of General Practice. 2009; 15(4): 207–211. DOI: https://doi.org/10.3109/13814780903452150 

Osterberg L, Blaschke T. Adherence to medication. New England Journal of Medicine. 2005; 353(5): 487–497. DOI: https://doi.org/10.1056/NEJMra050100 

Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, et al. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. Journal of the American Society of Hypertension. 2015; 9(6): 420–426.e2. DOI: https://doi.org/10.1016/j.jash.2015.04.004 

Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: From methodological issues to cardiovascular outcomes. Journal of Hypertension. 2017; 35(6): 1133–1144. DOI: https://doi.org/10.1097/HJH.0000000000001299 

Tan X, Patel I, Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). INNOVATIONS in Pharmacy. 2014; 5(3): 5. DOI: https://doi.org/10.24926/iip.v5i3.347 

de Oliveira-Filho AD, Morisky DE, Neves SJ, Costa FA, de Lyra DP Jr., The 8-item Morisky Medication Adherence Scale: Validation of a Brazilian-Portuguese version in hypertensive adults. Research in Social & Administrative Pharmacy. 2014; 10(3): 554–561. DOI: https://doi.org/10.1016/j.sapharm.2013.10.006 

Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. Journal of Clinical Hypertens (Greenwich). 2008; 10(5): 348–354. DOI: https://doi.org/10.1111/j.1751-7176.2008.07572.x 

Krousel-Wood M, Muntner P, Jannu A, Desalvo K, Re RN. Reliability of a medication adherence measure in an outpatient setting. The American Journal of the Medical Sciences. 2005; 330(3): 128–133. DOI: https://doi.org/10.1097/00000441-200509000-00006 

Ben AJ, Neumann CR, Mengue SS. Teste de Morisky-Green e Brief Medication Questionnaire para avaliar adesão a medicamentos. Revista de Saúde Pública. 2012; 46: 279–289. DOI: https://doi.org/10.1590/S0034-89102012005000013 

Pan J, Hu B, Wu L, Wang H, Lei T, Liu Z. The translation, reliability and validity of the Chinese version of the Hill-Bone Compliance to High Blood Pressure Therapy Scale in adults with hypertension. Patient Preference and Adherence. 2020; 14: 1853. DOI: https://doi.org/10.2147/PPA.S268031 

Lambert EV, Steyn K, Stender S, Everage N, Fourie JM, Hill M. Cross-cultural validation of the Hill-Bone Compliance to High Blood Pressure Therapy Scale in a South African, primary healthcare setting. Ethnicity & Disease. 2006; 16(1): 286–291. 

Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the differentiation between nonadherence and nonresponse to antihypertensive treatment. Journal of Clinical Epidemiology. 2008; 61(3): 282–288. DOI: https://doi.org/10.1016/j.jclinepi.2007.04.007 

Gozum S, Hacihasanoglu R. Reliability and validity of the Turkish adaptation of medication adherence self-efficacy scale in hypertensive patients. European Journal of Cardiovascular Nursing. 2009; 8(2): 129–136. DOI: https://doi.org/10.1016/j.ejcnurse.2008.10.006 

Porter AK, Taylor SR, Yabut AH, Al-Achi A. Impact of a pill box clinic to improve systolic blood pressure in veterans with uncontrolled hypertension taking 3 or more antihypertensive medications. Journal of Managed Care & Specialty Pharmacy. 2014; 20(9): 905–911. DOI: https://doi.org/10.18553/jmcp.2014.20.9.905 

Lee JY, Greene PG, Douglas M, Grim C, Kirk KA, Kusek JW, et al. Appointment attendance, pill counts, and achievement of goal blood pressure in the African American Study of Kidney Disease and Hypertension Pilot Study. Controlled Clinical Trials. 1996; 17(4 Suppl): 34s–39s. DOI: https://doi.org/10.1016/S0197-2456(97)82680-3 

García Navarro M, Orozco Beltrán D, Gil Guillén V, Carratalá Munuera C, Terol Moltó C, Merino Sánchez J. Relationship between drug compliance and degree of control in patients with hypertension, diabetes or dyslipidemia. Medicina clínica (Barc). 2001; 116(Suppl 2): 141–146. 

Tedla YG, Bautista LE. Drug side effect symptoms and adherence to antihypertensive medication. American Journal of Hypertension. 2016; 29(6): 772–779. DOI: https://doi.org/10.1093/ajh/hpv185 

Adeyemo A, Tayo BO, Luke A, Ogedegbe O, Durazo-Arvizu R, Cooper RS. The Nigerian anti-hypertensive adherence trial (NA-HAT): A community-based randomized trial. Journal of Hypertension. 2013; 31(1): 201. DOI: https://doi.org/10.1097/HJH.0b013e32835b0842 

Elzubier AG, Husain AA, Suleiman IA, Hamid ZA. Drug compliance among hypertensive patients in Kassala, eastern Sudan. Eastern Mediterranean Health Journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2000; 6(1): 100–105. DOI: https://doi.org/10.26719/2000.6.1.100 

Maro EE, Lwakatare J. Medication compliance among Tanzanian hypertensives. East African Medical Journal. 1997; 74(9): 539–542. 

Perseguer-Torregrosa Z, Orozco-Beltrán D, Gil-Guillen VF, Pita-Fernandez S, Carratalá-Munuera C, Pallares-Carratalá V, et al. Magnitude of pharmacological nonadherence in hypertensive patients taking antihypertensive medication from a community pharmacy in Spain. Journal of Managed Care Pharmacy. 2014; 20(12): 1217–1225. DOI: https://doi.org/10.18553/jmcp.2014.20.12.1217 

van Onzenoort HA, Verberk WJ, Kessels AG, Kroon AA, Neef C, van der Kuy PH, et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. American Journal of Hypertension. 2010; 23(2): 149–154. DOI: https://doi.org/10.1038/ajh.2009.207 

Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clinical Pharmacology & Therapeutics. 2014; 95(6): 617–626. DOI: https://doi.org/10.1038/clpt.2014.59 

Damasceno A, Azevedo A, Silva-Matos C, Prista A, Diogo D, Lunet N. Hypertension prevalence, awareness, treatment, and control in Mozambique: Urban/rural gap during epidemiological transition. Hypertension. 2009; 54(1): 77–83. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.109.132423 

Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decisions. Journal of Hypertension. 2001; 19(2): 335–341. DOI: https://doi.org/10.1097/00004872-200102000-00022 

Richter LH, Jacobs CM, Mahfoud F, Kindermann I, Böhm M, Meyer MR. Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence. Analytica chimica acta. 2019; 1070: 69–79. DOI: https://doi.org/10.1016/j.aca.2019.04.026 

Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, et al. Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: The HeartStrong randomized clinical trial. JAMA Internal Medicine. 2017; 177(8): 1093–1101. DOI: https://doi.org/10.1001/jamainternmed.2017.2449 

Wetzels GE, Nelemans PJ, Schouten JS, Dirksen CD, van der Weijden T, Stoffers HE, et al. Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. American Journal of Hypertension. 2007; 20(2): 119–125. DOI: https://doi.org/10.1016/j.amjhyper.2006.07.018 

Leenen FH, Wilson TW, Bolli P, Larochelle P, Myers M, Handa SP, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring. Canadian Journal of Cardiology. 1997; 13(10): 914–920. 

Polonia J, Salgueiro A, Silva J, Barbosa L. Importance of the directly observed treatment intake on the approach of patients with resistant hypertension. Journal of Hypertension. 2018; 36: E65. DOI: https://doi.org/10.1097/01.hjh.0000539142.48753.af 

Ruzicka M, Leenen FH, Ramsay T, Bugeja A, Edwards C, McCormick B, et al. Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Internal Medicine. 2019; 179(10): 1433–1434. DOI: https://doi.org/10.1001/jamainternmed.2019.1455 

Eskås PA, Heimark S, Eek Mariampillai J, Larstorp AC, Fadl Elmula FE, Høieggen A. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016; 25(4): 199–205. DOI: https://doi.org/10.3109/08037051.2015.1121706 

Pio-Abreu A, Trani-Ferreira F, Silva GV, Bortolotto LA, Drager LF. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart. 2022; 108(24): 1952–1956. DOI: https://doi.org/10.1136/heartjnl-2022-320802 

Hameed M, Tebbit L, Jacques N, Thomas M, Dasgupta I. Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic. Journal of Human Hypertension. 2016; 30(2): 83–89. DOI: https://doi.org/10.1038/jhh.2015.38 

Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertension Research. 2011; 34(1): 87–90. DOI: https://doi.org/10.1038/hr.2010.183 

Štrauch B, Petrák O, Zelinka T, Rosa J, Šomlóová Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension. 2013; 31(12): 2455–2461. DOI: https://doi.org/10.1097/HJH.0b013e3283652c61 

Florczak E, Tokarczyk B, Warchoł-Celińska E, Szwench-Pietrasz E, Prejbisz A, Gosk M, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. Polskie Archiwum Medycyny Wewnętrznej. 2015; 125(1–2): 65–72. DOI: https://doi.org/10.20452/pamw.2648 

Tanna S, Ogwu J, Lawson G. Hyphenated mass spectrometry techniques for assessing medication adherence: advantages, challenges, clinical applications and future perspectives. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58(5): 643–663. DOI: https://doi.org/10.1515/cclm-2019-0820 

Mallion JM, Dutrey-Dupagne C, Vaur L, Genes N, Renault M, Elkik F, et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. Journal of Hypertension. 1996; 14(1): 137–144. DOI: https://doi.org/10.1097/00004872-199601000-00018 

Mehta SJ, Volpp KG, Troxel AB, Day SC, Lim R, Marcus N, et al. Electronic pill bottles or bidirectional text messaging to improve hypertension medication adherence (Way 2 Text): A randomized clinical trial. Journal of General Internal Medicine. 2019; 34(11): 2397–2404. DOI: https://doi.org/10.1007/s11606-019-05241-x 

Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. Journal of Hypertension. 2013; 31(4): 766–774. DOI: https://doi.org/10.1097/HJH.0b013e32835e2286 

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Gulsin GS, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017; 70(5): 1042–1048. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.09631 

Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics. 1999; 21(6): 1074–1090. DOI: https://doi.org/10.1016/S0149-2918(99)80026-5 

Van Onzenoort HA, Verberk WJ, Kessels AG, Kroon AA, Neef C, van der Kuy P-HM, et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. American Journal of Hypertension. 2010; 23(2): 149–154. DOI: https://doi.org/10.1038/ajh.2009.207 

Rudd P, Byyny RL, Zachary V, LoVerde ME, Mitchell WD, Titus C, et al. Pill count measures of compliance in a drug trial: Variability and suitability. American Journal of Hypertension. 1988; 1(3, Pt 1): 309–312. DOI: https://doi.org/10.1093/ajh/1.3.309 

Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261(22): 3273–3277. DOI: https://doi.org/10.1001/jama.1989.03420220087032 

Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clinical Pharmacology & Therapeutics. 1989; 46(2): 163–168. DOI: https://doi.org/10.1038/clpt.1989.121 

Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews. 2014(11): CD000011. DOI: https://doi.org/10.1002/14651858.CD000011.pub4 

Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: A systematic literature review and meta-analysis. Drugs. 2013; 73(6): 545–562. DOI: https://doi.org/10.1007/s40265-013-0041-3 

Bramley TJ, Nightengale BS, Frech-Tamas F, Gerbino PP. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. Journal of Managed Care Pharmacy. 2006; 12(3): 239–245. DOI: https://doi.org/10.18553/jmcp.2006.12.3.239 

Mallion J-M, Baguet J-P, Siche J-P, Tremel F, De Gaudemaris R. Compliance, electronic monitoring and antihypertensive drugs. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension. 1998; 16(1): S75–79. 

Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bulletin of the World Health Organization. 2002; 80(1): 33–39. 

Ayoade A, Oladipo I. Evaluation of the correlation between self-report and electronic monitoring of adherence to hypertension therapy. Blood Pressure. 2012; 21(3): 161–166. DOI: https://doi.org/10.3109/08037051.2012.679029 

Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: A review of systematic reviews. Frontiers in Pharmacology. 2013; 4: 91. DOI: https://doi.org/10.3389/fphar.2013.00091 

Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLOS medicine. 2018; 15(7): e1002595. DOI: https://doi.org/10.1371/journal.pmed.1002595 

Basu S, Garg S, Sharma N, Singh MM. Improving the assessment of medication adherence: Challenges and considerations with a focus on low-resource settings. Tzu-Chi Medical Journal. 2019; 31(2): 73. DOI: https://doi.org/10.4103/tcmj.tcmj_177_18 

Lawson G, Fish R. Directly observed administration of antihypertensive medication prior to ambulatory blood pressure monitoring—A useful tool for investigating “resistant hypertension.” Journal of Hypertension. 2021; 39: e358. DOI: https://doi.org/10.1097/01.hjh.0000748684.71720.64 

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75(6): 1334–1357. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.15026 

Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJ, et al. Nonadherence in hypertension: How to develop and implement chemical adherence testing. Hypertension. 2022; 79(1): 12–23. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.121.17596 

de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ. Medication adherence in patients with apparent resistant hypertension: Fndings from the SYMPATHY trial. British Journal of Clinical Pharmacology. 2018; 84(1): 18–24. DOI: https://doi.org/10.1111/bcp.13402 

Avataneo V, De Nicolò A, Rabbia F, Perlo E, Burrello J, Berra E, et al. Therapeutic drug monitoring–guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. British Journal of Clinical Pharmacology. 2018; 84(11): 2535–2543. DOI: https://doi.org/10.1111/bcp.13706 

Peeters LE, Feyz L, Boersma E, Daemen J, van Gelder T, Koch BC, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension. 2020; 76(1): 80–86. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.15038 

Pucci M, Martin U. Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: Rates, reasons and reactions. Journal of Human Hypertension. 2017; 31(4): 253–257. DOI: https://doi.org/10.1038/jhh.2016.69 

Maurer HH. Perspectives of liquid chromatography coupled to low- and high-resolution mass spectrometry for screenin